Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NNC0721-8060 · 1 trial · 2 indications
Measured as number of events.
Measured as number of events.
Measured as percentage change in body weight.
| Arm | Type | Description |
|---|---|---|
| NNC0721-8060 | EXPERIMENTAL | Participants will receive subcutaneous injection of NNC0721-8060. |
| Semaglutide | ACTIVE_COMPARATOR | Participants will receive subcutaneous injection of semaglutide. |
| Placebo | PLACEBO_COMPARATOR | Participants will receive subcutaneous injection of placebo. |
| Name | Type | Description |
|---|---|---|
| NNC0721-8060 | DRUG | NNC0721-8060 will be administered subcutaneously. |
| Semaglutide | DRUG | Semaglutide will be administered subcutaneously. |
| Placebo | DRUG | Placebo will be administered subcutaneously. |
Inclusion Criteria: * Male or female (sex at birth). * Age 18-55 years (both inclusive) at the time of signing informed consent. * Body Mass Index (BMI) 27.0-34.9 kilograms per square metre (kg/m\^2) (both inclusive) at screening, with overweight due to excess adipose tissue as judged by the invest...
NNC0721-8060 is an investigational small molecule being developed for the treatment of overweight and obesity. It is currently in Phase 1 clinical development, with a first-in-human study planned to evaluate how it works in people living with overweight or obesity.
NNC0721-8060 is being developed by Novo Nordisk A/S, a pharmaceutical company listed on the stock exchange under the ticker symbol NVO. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug.
NNC0721-8060 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to assess its safety and effectiveness in humans.
NNC0721-8060 is being studied in a Phase 1 clinical trial with the identifier NCT07767175. This first-in-human study is designed to evaluate how the drug works in people with overweight or obesity, with an enrollment of 142 participants in the United States.
No alternative names for NNC0721-8060 have been disclosed. The drug is identified solely by its code name NNC0721-8060 in clinical trial registries and public information.